Enveric Biosciences Future Growth
Future criteria checks 0/6
Enveric Biosciences's earnings are forecast to decline at 21.3% per annum. EPS is expected to grow by 39.1% per annum.
Key information
-21.3%
Earnings growth rate
39.1%
EPS growth rate
Pharmaceuticals earnings growth | 19.7% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 01 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -21 | N/A | N/A | 1 |
12/31/2025 | N/A | -20 | N/A | N/A | 1 |
12/31/2024 | N/A | -18 | N/A | N/A | 1 |
6/30/2024 | N/A | -11 | -10 | -10 | N/A |
3/31/2024 | N/A | -15 | -12 | -12 | N/A |
12/31/2023 | N/A | -17 | -14 | -14 | N/A |
9/30/2023 | N/A | -23 | -16 | -16 | N/A |
6/30/2023 | N/A | -23 | -18 | -18 | N/A |
3/31/2023 | N/A | -19 | -18 | -18 | N/A |
12/31/2022 | N/A | -19 | -18 | -17 | N/A |
9/30/2022 | N/A | -52 | -19 | -18 | N/A |
6/30/2022 | N/A | -52 | -16 | -15 | N/A |
3/31/2022 | N/A | -50 | -14 | -13 | N/A |
12/31/2021 | N/A | -49 | -12 | -11 | N/A |
9/30/2021 | N/A | -11 | -10 | -10 | N/A |
6/30/2021 | N/A | -9 | -9 | -8 | N/A |
3/31/2021 | N/A | -9 | -7 | -6 | N/A |
12/31/2020 | N/A | -7 | -4 | -4 | N/A |
9/30/2020 | N/A | -3 | -2 | -2 | N/A |
6/30/2020 | N/A | -3 | -1 | -1 | N/A |
3/31/2020 | N/A | -3 | -1 | -1 | N/A |
12/31/2019 | N/A | -2 | -1 | -1 | N/A |
9/30/2019 | N/A | -3 | -1 | -1 | N/A |
12/31/2018 | N/A | -2 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLZA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SLZA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SLZA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if SLZA's revenue is forecast to grow faster than the German market.
High Growth Revenue: SLZA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SLZA's Return on Equity is forecast to be high in 3 years time